therapy refractory
Showing 1 - 25 of >10,000
MDDs Trial in Tianjin (N-acetylcysteine, comparator of N-acetylcysteine)
Recruiting
- Major Depressive Disorders
- N-acetylcysteine
- placebo comparator of N-acetylcysteine
-
Tianjin, Tianjin, ChinaTianjin Anding Hospital
Sep 21, 2022
Metastatic Castration Resistant Prostate Cancer Trial in United States (LAVA-1207)
Recruiting
- Metastatic Castration Resistant Prostate Cancer
- LAVA-1207
-
Tampa, Florida
- +3 more
Nov 18, 2022
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse
- anti Tim-3/CD123 CAR-T cell therapy
-
Xuzhou, Jiangsu, ChinaKailin Xu
Nov 4, 2023
Pathologically Confirmed Cancer Refractory to Conventional Therapy, Refractory Cancer, Metastatic Cancer Trial in Santa Monica
Not yet recruiting
- Pathologically Confirmed Cancer Refractory to Conventional Therapy
- +7 more
- SNK02
-
Santa Monica, CaliforniaSarcoma Oncology Center
Aug 10, 2023
Relapse/Refractory Multiple Myeloma Trial in Hangzhou (DeepTag-GPRC5D Targeted CAR T-cells)
Recruiting
- Relapse/Refractory Multiple Myeloma
- DeepTag-GPRC5D Targeted CAR T-cells
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Oct 10, 2023
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- (no location specified)
Nov 9, 2023
AML, MDS Trial in Tuebingen (Decitabine, Venetoclax)
Recruiting
- AML
- MDS
-
Tuebingen, Baden-Wuerttemberg, GermanyUniversity Hospital
Nov 30, 2023
Steroid-refractory Acute Graft-versus-host Disease Trial (MC0518, BAT)
Not yet recruiting
- Steroid-refractory Acute Graft-versus-host Disease
- MC0518
- BAT
- (no location specified)
Oct 4, 2023
Relapsed/ Refractory Multiple Myeloma Trial (GC012F)
Not yet recruiting
- Relapsed/ Refractory Multiple Myeloma
- GC012F
- (no location specified)
Apr 28, 2023
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022
Not yet recruiting
- Cancer
- Relapsed/Refractory Large B-cell Lymphoma (LBCL)
- Fludarabine (30 mg/m^2)
- +2 more
- (no location specified)
Jul 25, 2023
Refractory Mycosis Fungoides Trial in Scottsdale (drug, other, radiation)
Completed
- Refractory Mycosis Fungoides
- Aminolevulinic Acid Hydrochloride
- +3 more
-
Scottsdale, ArizonaMayo Clinic in Arizona
Jan 3, 2023
Nontuberculous Mycobacterium Infection, Mycobacterium Abscessus Infection Trial (Delpazolid)
Not yet recruiting
- Nontuberculous Mycobacterium Infection
- Mycobacterium Abscessus Infection
- (no location specified)
Aug 21, 2023
Hematological Malignancies, CMV Infection Trial in Belgium (CMV-specific T cells, Standard anti-viral therapy)
Completed
- Hematological Malignancies
- CMV Infection
- CMV-specific T cells
- Standard anti-viral therapy
-
Gent, Oost-Vlaanderen, Belgium
- +7 more
Dec 19, 2022
Follicular Lymphoma Trial (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate)
Not yet recruiting
- Follicular Lymphoma
- Axicabtagene Ciloleucel
- +5 more
- (no location specified)
Sep 21, 2023
Refractory HIV Associated Kaposi Sarcoma Trial (Dostarlimab in Combination Antiretroviral Therapy)
Not yet recruiting
- Refractory HIV Associated Kaposi Sarcoma
- Dostarlimab in Combination Antiretroviral Therapy
- (no location specified)
Dec 2, 2022
Immune-related Adverse Events Refractory to Standard Therapy and
Recruiting
- Immune-related Adverse Event
- Extracorporeal photopheresis
- Other immunosuppressive or immunomodulatory drugs
-
Munich, GermanyLMU Klinikum Hauttumorzentrum
Jan 17, 2023
Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))
Not yet recruiting
- Lymphoma, B-Cell
- +7 more
- Adaptive Bridging Radiation Therapy (ABRT)
-
Boston, MassachusettsDana-Farber Cancer Institute
Aug 16, 2023
Relapsed/Refractory Multiple Myeloma Trial in Philadelphia (Cevostamab)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
-
Philadelphia, PennsylvaniaHospital of the University of Pennsylvania
Apr 7, 2023
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Low Dose Radiation Therapy)
Recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Low Dose Radiation Therapy
-
Houston, TexasM D Anderson Cancer Center
Jan 30, 2023
Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,
Recruiting
- Lupus Nephritis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Denver, Colorado
- +1 more
Jul 7, 2023
Relapsed/Refractory Aggressive B-Cell Malignancies Trial (ONCT-808, Bridging Therapy)
Not yet recruiting
- Relapsed/Refractory Aggressive B-Cell Malignancies
- ONCT-808
- Bridging Therapy
- (no location specified)
Jan 19, 2023
Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Refractory Thyroid Gland Follicular Carcinoma
Recruiting
- Refractory Thyroid Gland Carcinoma
- +3 more
- 177Lu-DOTA-EB-FAPI 1 radionuclide therapy
- +2 more
-
Xiamen, ChinaThe First Affiliated Hospital of Xiamen University
Nov 3, 2022
Large B-cell Lymphoma, B-cell Lymphoma Trial in Houston (Magrolimab, Rituximab, CAR T leukapheresis)
Not yet recruiting
- Large B-cell Lymphoma
- B-cell Lymphoma
- Magrolimab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jun 29, 2023
Multiple Myeloma in Relapse Trial in Aurora (Selinexor, Pomalidomide, Daratumumab)
Recruiting
- Multiple Myeloma in Relapse
- Selinexor
- +4 more
-
Aurora, ColoradoUniversity of Colorado Hospital
Jan 31, 2023
Immune-related Colitis, Colitis Trial in Minneapolis (RMT, Placebo)
Not yet recruiting
- Immune-related Colitis
- Colitis
- RMT
- Placebo
-
Minneapolis, MinnesotaUniversity of Minnesota
Feb 4, 2023